- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05349617
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
September 8, 2023 updated by: Bavarian Nordic
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Co-primary Objectives:
- To compare the anti-CHIKV serum neutralizing antibody (SNA) response to PXVX0317 and placebo at Day 22, as measured by geometric mean titer (GMT) and clinically relevant difference in seroresponse rate (PXVX0317 minus placebo) in adults ≥65 years of age.
- To evaluate the safety of PXVX0317 in adults ≥65 years of age
Secondary Objectives:
- To compare the anti-CHIKV SNA response to PXVX0317 and placebo at Day 15 and Day 183, as measured by GMT and seroresponse rate.
- To compare the anti-CHIKV SNA response to PXVX0317 and placebo in participants ≥65 to <75 and ≥75 years of age as measured by GMT and seroresponse rate.
Study Type
Interventional
Enrollment (Actual)
413
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sufia Muhammad, MD
- Phone Number: (346) 732-7331
- Email: muhammads@ebsi.com
Study Contact Backup
- Name: Patrick Ajiboye, MD
- Phone Number: (240) 841-1378
- Email: ajiboyep@ebsi.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33173
- Suncoast Research Associates, LLC
-
Miami Lakes, Florida, United States, 33014
- Panax Clinical Research
-
Saint Petersburg, Florida, United States, 33705
- Global Clinical Research Professionals (GCP)
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- AMR Kansas City
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc.
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Coastal Carolina Research Center
-
-
Texas
-
Houston, Texas, United States, 77065
- DM Clinical Research CyFair
-
San Antonio, Texas, United States, 78249
- BHFC Research
-
Tomball, Texas, United States, 77375
- DM Clinical Research Tomball
-
-
Wisconsin
-
West Bend, Wisconsin, United States, 53095
- Spaulding Clinical
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Able and willing to provide informed consent voluntarily signed by participant. Must verbalize understanding of the general procedures of, and reason for the study.
- Males or females, ≥65 years of age.
- Able to complete all scheduled visits and comply with all study procedures.
- Women who are not of childbearing potential (CBP): surgically sterile (at least six weeks post bilateral tubal ligation, bilateral oophorectomy or hysterectomy); or postmenopausal (defined as a history of ≥12 consecutive months without menses prior to randomization in the absence of other pathologic or physiologic causes, following cessation of exogenous post menopausal sex-hormonal treatment).
- Participants must be in stable health in the opinion of the investigator for at least 30 days prior to screening (eg, no hospital admission for acute illness in the last 30 days prior to screening).
Exclusion Criteria:
- Participation or planned participation in an investigational clinical trial (eg, vaccine, drug, medical device, or medical procedure) within 30 days of Day 1 and for the duration of the study. Note: Participation in an observational trial or follow-up phase of a trial may be allowed; however, these instances should be discussed with the sponsor's medical monitor (MM) prior to enrollment.
- Prior receipt of any CHIKV vaccine.
- Positive laboratory evidence of current infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
- Body mass index (BMI) ≥35 kg/m^2
- History of any known or suspected allergy or history of anaphylaxis to any component of the investigational product (IP).
- History of any known congenital or acquired immunodeficiency or immunosuppressive condition that could impact response to vaccination (eg, leukemia, lymphoma, malignancy, functional or anatomic asplenia, alcoholic cirrhosis). Note: History of basal cell and squamous cell carcinoma of the skin or carcinoma in situ of the cervix considered cured would not be exclusionary. History of a malignancy considered cured from over five years from the date of screening with minimal risk of recurrence is not exclusionary.
- Prior or anticipated use of systemic immunomodulatory or immunosuppressive medications from six months prior to screening through Day 22. Note: Systemic corticosteroid use at a dose or equivalent dose of 20 mg of prednisone daily for 14 days or more within 90 days of screening through Day 22 is exclusionary. The use of inhaled, intranasal, topical, or ocular steroids is allowed.
- Bleeding disorder or receipt of anticoagulants in the 21 days prior to screening, contraindicating intramuscular (IM) vaccination, as judged by the investigator.
- Moderate or severe acute illness with or without fever (oral temperature ≥100.4°F or 38.0°C).
- Receipt or anticipated receipt of immunoglobulin from 180 days prior to screening through Day 22.
- Medical condition (such as dementia) that, in the opinion of the investigator, could adversely impact the participant's participation in or conduct of the study.
- Evidence of substance abuse that, in the opinion of the investigator, could adversely impact the participant's participation in or conduct of the study.
- Identified as an investigator or employee of an Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse) of the investigator or employee with direct involvement in the proposed study.
- Receipt or anticipated receipt of any vaccine from 30 days prior to Day 1 through Day 22.
- Receipt or anticipated receipt of blood or blood-derived products from 90 days prior to screening through Day 22.
- Any planned elective surgery that may interfere with study participation or conduct.
- Any other medical condition that, in the opinion of the investigator, could adversely impact the participant's participation in or conduct of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 - PXVX0317
|
PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
|
Placebo Comparator: Group 2 - Placebo
|
Placebo is comprised of formulation buffer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-CHIKV SNA GMTs at Day 22
Time Frame: 21 days post vaccination
|
Anti-CHIKV SNA GMT and associated 95% CIs at Day 22 for PXVX0317 and placebo.
|
21 days post vaccination
|
Incidence of solicited adverse events (AE)
Time Frame: 7 days post vaccination
|
Incidence of solicited AEs through Day 8
|
7 days post vaccination
|
Incidence of unsolicited AEs
Time Frame: 28 days post vaccination
|
Incidence of unsolicited AEs through Day 29
|
28 days post vaccination
|
Incidence of Serious Adverse Events (SAE)
Time Frame: 182 days post vaccination
|
Incidence of SAEs through Day 183
|
182 days post vaccination
|
Incidence of Medically Attended Adverse Events (MAAE)
Time Frame: 182 days post vaccination
|
Incidence of MAAEs through Day 183
|
182 days post vaccination
|
Incidence of Adverse Events of Special Interest (AESI)
Time Frame: 182 days post vaccination
|
Incidence of AESI through Day 183
|
182 days post vaccination
|
Anti-CHIKV SNA seroresponse rates at Day 22 in baseline seronegative participants
Time Frame: 21 days post vaccination
|
Difference in anti-CHIKV SNA seroresponse rate (PXVX0317 minus placebo) and associated 95% confidence interval (CI) at Day 22.
|
21 days post vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-CHIKV SNA seroresponse rates at Days 15 and 183
Time Frame: 182 days post vaccination
|
Difference in anti-CHIKV SNA seroresponse rate (PXVX0317 minus placebo) with associated 95% CIs at Day 15 and Day 183.
|
182 days post vaccination
|
Anti-CHIKV SNA GMTs at Days 15 and 183
Time Frame: 182 days post vaccination
|
Anti-CHIKV SNA GMTs by study arm with associated 95% CIs at Day 15 and Day 183.
|
182 days post vaccination
|
Anti-CHIKV SNA Geometric Mean Fold Increase (GMFI)
Time Frame: 182 days post vaccination
|
Geometric mean fold increase (GMFI) from Day 1 to subsequent collection time points.
|
182 days post vaccination
|
Subjects with anti-CHIKV SNA titer ≥15 and 4-fold rise over baseline
Time Frame: 182 days post vaccination
|
Number and percentage of participants with an anti-CHIKV SNA titer ≥15 and 4-fold rise over baseline.
|
182 days post vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 12, 2022
Primary Completion (Actual)
June 19, 2023
Study Completion (Actual)
August 8, 2023
Study Registration Dates
First Submitted
April 21, 2022
First Submitted That Met QC Criteria
April 21, 2022
First Posted (Actual)
April 27, 2022
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 8, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EBSI-CV-317-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chikungunya Virus
-
Bavarian NordicEmergent BioSolutionsCompleted
-
Valneva Austria GmbHActive, not recruitingChikungunya Virus InfectionUnited States
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)CompletedChikungunya Virus InfectionPuerto Rico
-
National Institutes of Health Clinical Center (CC)CompletedDengue Virus | Zika Virus | Chikungunya Virus InfectionsUnited States
-
University Hospital Center of MartiniqueUnknownInfected by Chikungunya VirusMartinique
-
Assistance Publique Hopitaux De MarseilleTerminated
-
Valneva Austria GmbHCompletedChikungunya Virus InfectionUnited States
-
Bavarian NordicEmergent BioSolutionsCompletedChikungunya VirusUnited States
-
ModernaTX, Inc.Defense Advanced Research Projects AgencyCompletedChikungunya VirusUnited States
-
Valneva Austria GmbHCompletedChikungunya Virus InfectionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States